
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9245845/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, The, 2021, 397, 1637-1645.	13.7	1,374
2	BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology, 2010, 49, 2217-2219.	1.9	187
3	Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: Results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis and Rheumatism, 2002, 46, 906-912.	6.7	162
4	Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1087-1093.	0.9	162
5	Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: Results from a large observational inception study. Arthritis and Rheumatism, 2003, 48, 46-53.	6.7	152
6	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology, 2020, 59, e1-e23.	1.9	128
7	Placenta growth factor (PIGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid. Clinical and Experimental Immunology, 2000, 119, 182-188.	2.6	105
8	The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology, 2019, 58, e3-e42.	1.9	96
9	Clinical Utility of Random Anti–Tumor Necrosis Factor Drug–Level Testing and Measurement of Antidrug Antibodies on the Longâ€∓erm Treatment Response in Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 2011-2019.	5.6	90
10	Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2017, 76, 497-503.	0.9	88
11	The performance of anti–cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: Results from the Norfolk Arthritis Register. Arthritis and Rheumatism, 2007, 56, 2929-2935.	6.7	84
12	Alkaptonuria. Rare Diseases (Austin, Tex ), 2013, 1, e27475.	1.8	82
13	Quantitation of microcirculatory abnormalities in patients with primary Raynaud's phenomenon and systemic sclerosis by video capillaroscopy. Rheumatology, 2000, 39, 506-512.	1.9	79
14	Reduced disability at five years with early treatment of inflammatory polyarthritis: Results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis and Rheumatism, 2001, 44, 1033-1042.	6.7	77
15	A Multicenter, Randomized, Placeboâ€Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2019, 71, 1437-1449.	5.6	77
16	Time to first occurrence of erosions in inflammatory polyarthritis: Results from a prospective community-based study. Arthritis and Rheumatism, 2001, 44, 1248-1253.	6.7	68
17	Diagnostic yield of FDG-PET/CT in fever ofÂunknown origin: a systematic review, meta-analysis, and Delphi exercise. Clinical Radiology, 2017, 72, 764-771.	1.1	63
18	Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds. Annals of the Rheumatic Diseases, 2016, 75, 2080-2086.	0.9	61

#	Article	IF	CITATIONS
19	INCREASED NAILFOLD CAPILLARY DIMENSIONS IN PRIMARY RAYNAUD'S PHENOMENON AND SYSTEMIC SCLEROSIS. Rheumatology, 1996, 35, 1127-1131.	1.9	57
20	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology, 2020, 59, 487-494.	1.9	56
21	BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology, 2010, 49, 1197-1199.	1.9	49
22	BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology, 2011, 50, 2311-2313.	1.9	42
23	The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis—Executive summary. Rheumatology, 2019, 58, 220-226.	1.9	38
24	Increasing age at symptom onset is associated with worse radiological damage at presentation in patients with early inflammatory polyarthritis. Annals of the Rheumatic Diseases, 2007, 66, 389-393.	0.9	36
25	Erosions in inflammatory polyarthritis are symmetrical regardless of rheumatoid factor status: results from a primary careâ€based inception cohort of patients. Rheumatology, 2002, 41, 246-252.	1.9	30
26	Polymorphisms in the tumour necrosis factor gene are not associated with severity of inflammatory polyarthritis. Annals of the Rheumatic Diseases, 2004, 63, 280-284.	0.9	30
27	The rheumatoid arthritis articular damage score: first steps in developing a clinical index of long term damage in RA. Annals of the Rheumatic Diseases, 2002, 61, 20-23.	0.9	27
28	Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor–treated rheumatoid arthritis patients. Rheumatology, 2019, 58, 2162-2169.	1.9	26
29	Management of Acute Nontraumatic Upper Limb Ischemia. Angiology, 1999, 50, 715-720.	1.8	23
30	The predictors of and reasons for non-adherence in an observational cohort of patients with rheumatoid arthritis commencing methotrexate. Rheumatology, 2020, 59, 213-223.	1.9	22
31	Development and Validation of a Patient Reported Experience Measure (PREM) for Patients with Rheumatoid Arthritis (RA) and other Rheumatic Conditions. Current Rheumatology Reviews, 2015, 11, 1-7.	0.8	21
32	The relationship between citations, downloads and alternative metrics in rheumatology publications: a bibliometric study. Rheumatology, 2020, 59, 277-280.	1.9	21
33	Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis. Arthritis Research and Therapy, 2012, 14, R109.	3.5	18
34	Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 1800-1809.	5.6	18
35	Hello from the new Editor-in-Chief. Rheumatology, 2019, 58, 1-2.	1.9	14
36	The sesamoid index in psoriatic arthropathy. Skeletal Radiology, 2005, 34, 217-220.	2.0	13

#	Article	IF	CITATIONS
37	Recent pharmacological advances in the management of gout. Rheumatology, 2018, 57, 951-958.	1.9	13
38	Drug-induced rheumatic diseases. Current Opinion in Rheumatology, 2012, 24, 182-186.	4.3	12
39	The prevalence of osteoporosis in an older population with very high body mass index: evidence for an association. International Journal of Clinical Practice, 2014, 68, 771-774.	1.7	11
40	Prevalence of Paget's disease of bone in Lancaster: time for an update. Rheumatology, 2018, 57, 931-932.	1.9	11
41	A role for interleukins in ochronosis in a chondrocyte in vitro model of alkaptonuria. Clinical Rheumatology, 2016, 35, 1849-1856.	2.2	10
42	Use of biologics in SLE: a review of the evidence from a clinical perspective. Rheumatology, 2016, 55, 775-779.	1.9	10
43	Rapamycin for inclusion body myositis: targeting non-inflammatory mechanisms. Rheumatology, 2019, 58, 375-376.	1.9	10
44	The National Osteoporosis Guideline Group's new guidelines: what is new?. Rheumatology, 2009, 48, 327-329.	1.9	9
45	Predictors of fracture risk in patients with systemic lupus erythematosus. Lupus, 2018, 27, 1547-1551.	1.6	7
46	Twitter, #alternativefacts, careless whispers and Rheumatology. Rheumatology, 2018, 57, 773-774.	1.9	7
47	Predictors of fragility fracture and low bone mineral density in patients with a history of parental fracture. Osteoporosis and Sarcopenia, 2019, 5, 6-10.	1.9	7
48	The benefits and challenges of providing patient education digitally. Rheumatology, 2020, 59, 3591-3592.	1.9	7
49	Targeted literature review of current treatments and unmet need in moderate rheumatoid arthritis in the United Kingdom. Rheumatology, 2021, 60, 4972-4981.	1.9	7
50	ls it ever appropriate to discharge patients with rheumatoid arthritis?. Rheumatology, 2007, 46, 1631-1633.	1.9	6
51	Erosive amyloidosis of the wrist and knee associated with oligoclonal bands. Rheumatology, 1997, 36, 494-497.	1.9	5
52	Real-life experience of tocilizumab use in COVID-19 patients. Rheumatology, 2020, 59, 2163-2166.	1.9	5
53	The COVID-19 Vaccine Landscape: What a Rheumatologist Needs to Know. Journal of Rheumatology, 2021, 48, 1201-1204.	2.0	5
54	Osteoarticular cells tolerate short-term exposure to nitisinone—implications in alkaptonuria. Clinical Rheumatology, 2016, 35, 513-516.	2.2	4

#	Article	IF	CITATIONS
55	Are we failing patients in our assessment of treatment failure?. Rheumatology, 2019, 58, 561-562.	1.9	4
56	Do we need to perform MRI of the whole spine in addition to MRI of the sacroiliac joints in suspected spondyloarthropathy?. Clinical Radiology, 2019, 74, 409.e1-409.e6.	1.1	4
57	Is remission achievable in most patients with rheumatoid arthritis? Results suggest not. Rheumatology, 2019, 58, 187-188.	1.9	4
58	How rheumatologists assess disability in the current era needs an overhaul: focus on the Health Assessment Questionnaire. Rheumatology, 2020, 59, 267-268.	1.9	4
59	Referrals to hospital-based rheumatology and orthopaedic services: seeking direction. Rheumatology, 2005, 44, 1332-1333.	1.9	3
60	AB0708â€Delay To Diagnosis in Ankylosing Spondylitis: A Local Perspective. Annals of the Rheumatic Diseases, 2016, 75, 1146.3-1147.	0.9	3
61	AB0097â€The Presence of Staphylococcal Toxins in The Urine of Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 930.1-930.	0.9	3
62	Colchicine and the heart: old friends, old foes. Rheumatology, 2021, 60, 2035-2036.	1.9	3
63	Increasing body fat mass reverses bone loss in osteopenia as detected by dual-energy X-ray absorptiometry scans. European Journal of Rheumatology, 2016, 3, 1-4.	0.6	3
64	Disease Activity, Smoking, and Reproductive-related Predictors of Poor Prognosis in Patients with Very Early Inflammatory Polyarthritis. Journal of Rheumatology, 2011, 38, 429-433.	2.0	2
65	OP0292â€The Diagnosis of Osteoporosis Using BMD and T Score Measurements at Specific Skeletal Sites. Annals of the Rheumatic Diseases, 2014, 73, 172.2-172.	0.9	2
66	Osteoanabolic therapy: a valid option to reduce refracture risk after vertebral augmentation procedures?. Osteoporosis International, 2016, 27, 3387-3388.	3.1	2
67	Should Rheumatology be a core discipline of a chronic pain multi-disciplinary team?. Rheumatology, 2018, 57, 949-950.	1.9	2
68	Evidence-based practice is the gold standard and should be adhered to at all times—or should it?. Rheumatology, 2018, 57, 2067-2069.	1.9	2
69	Acroosteolysis in a patient with systemic lupus erythematosus/mixed connective tissue disease. Rheumatology, 2019, 58, 426-426.	1.9	2
70	COVID-19 and mortality in rare rheumatic diseases, a warning bell?. Rheumatology, 2021, 60, 1580-1581.	1.9	2
71	Paradoxically protective effect of glucocorticoids on bone mass and fragility fracture in a large cohort: a cross sectional study. Rheumatology Advances in Practice, 2022, 6, rkab089.	0.7	2
72	NICE guidance does not tally with clinical practicea district general experience. Rheumatology, 2007, 47, 222-223.	1.9	1

#	Article	IF	CITATIONS
73	Assessment of the impact of new UK guidelines on the management of aromatase inhibitor-associated bone loss. Rheumatology, 2008, 48, 197-198.	1.9	1
74	Isolated lower limb medium-vessel vasculitis: a new entity?. BMJ Case Reports, 2011, 2011, bcr0220113872-bcr0220113872.	0.5	1
75	E22. A Case of Rhabdomyolysis Induced by Febuxostat Therapy in a Patient with Hyperuricaemia and Chronic Renal Transplant Dysfunction. Rheumatology, 2015, , .	1.9	1
76	2015 EULAR–ACR recommendations for polymyalgia rheumatica: the message and next steps. Rheumatology, 2016, 55, 955-956.	1.9	1
77	AB0575â€Steroid Use Is Protective of Osteoporosis in Polymyalgia Rheumatica Patients: A Case-Control Study. Annals of the Rheumatic Diseases, 2016, 75, 1101.2-1101.	0.9	1
78	Have we had a paradigm change in the treatment of rheumatoid arthritis after the American Congress of Rheumatology 2015?: Table 1. Rheumatology, 2016, 55, 1531-1533.	1.9	1
79	Nitisinone therapy shows beneficial effects on the chondrocytes and extracellular matrix in the osteoarthropathy of alkaptonuria. Osteoarthritis and Cartilage, 2017, 25, S152.	1.3	1
80	Building the future of rheumatology: the role of national and international networks. Rheumatology, 2018, 57, 405-407.	1.9	1
81	AB0302â€The role of the biomarker 14–3–3 eta in rheumatoid arthritis: a review. , 2018, , .		1
82	The price of good health care. Rheumatology, 2019, 58, 931-932.	1.9	1
83	Symptomatic patients with P369S–R408Q mutations: familial Mediterranean fever or mixed auto-inflammatory syndrome?. BMJ Case Reports, 2019, 12, e228858.	0.5	1
84	FRI0081â€WITHDRAWAL OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN TH SARILUMAB OPEN-LABEL EXTEND STUDY: EFFICACY AND SAFETY ANALYSIS. , 2019, , .	E	1
85	Baseline retinal testing is no longer recommended for hydroxychloroquine users in the United Kingdom. Rheumatology, 2021, 60, 2037-2039.	1.9	1
86	PROMs vs. PREMs (Patient-Reported Experience Measures). , 2016, , 405-417.		1
87	AB0267â€Baseline predictors of response to methotrexate in early rheumatoid arthritis. , 2018, , .		1
88	AB1324â€Studying the relationship between body mass index, bmi, and bone mineral density, bmd, of lumbar vertebrae and femoral neck. , 2018, , .		1
89	Retrospective Analysis of Factors Associated with Fracture in 714 Patients with Polymyalgia Rheumatica. International Journal of Rheumatology, 2022, 2022, 1-6.	1.6	1
90	Safety of jakinibs: lessons from ORAL Surveillance. Rheumatology, 2022, 61, 4223-4225.	1.9	1

#	Article	IF	CITATIONS
91	Comment on: NICE guidance does not tally with clinical practicea district general experience: reply. Rheumatology, 2008, 47, 1736-1736.	1.9	0
92	Orthopaedics and Rehabilitation [84-85]: 84. A Comparison of Patients Referred after Fractures of the Forearm and Fractures of the Spine and HIP. Rheumatology, 2010, 49, i64-i65.	1.9	0
93	A survey of new to follow-up ratios in rheumatology outpatients departments. Clinical Medicine, 2011, 11, 99.2-100.	1.9	0
94	SAT0364â€Are differences of hip shape responsible for increased femoral neck fracture risk in post-menopausal women? Annals of the Rheumatic Diseases, 2013, 71, 595.2-595.	0.9	0
95	SAT0344â€Does proximal femur shape contribute to femoral neck fracture risk in osteoporotic individuals? Annals of the Rheumatic Diseases, 2013, 71, 588.3-589.	0.9	0
96	FRI0199â€Does Lower Bone Mineral Density in A Single Hip PREDICT Fracture Better than Average Bone Mineral Density across Both Hips?. Annals of the Rheumatic Diseases, 2014, 73, 454.2-455.	0.9	0
97	198. Very High Body Mass Index is Associated with Osteoporosis. Rheumatology, 2014, 53, i133-i133.	1.9	0
98	AB0928â€Do Osteoarthritic Cytokines Accelerate the Development of Ochronotic Arthropathy?. Annals of the Rheumatic Diseases, 2014, 73, 1107.2-1107.	0.9	0
99	A role for interleukins in the rapid progression of osteoarthritis in alkaptonuria. Osteoarthritis and Cartilage, 2014, 22, S61.	1.3	0
100	SAT0272â€The Use of Rituximab in Anca-Associated Vasculitides: Systematic Review. Annals of the Rheumatic Diseases, 2014, 73, 691.2-692.	0.9	0
101	FRI0063â€Changes in Bone Mass over Time in Subjects with Rheumatoid Arthritis: an Observational Study. Annals of the Rheumatic Diseases, 2014, 73, 404.2-404.	0.9	0
102	SAT0474â€Predictors of Bone Loss in Men Treated with Androgen Deprivation Therapy for Prostate Cancer: an Observational Study: Table 1 Annals of the Rheumatic Diseases, 2014, 73, 765.1-765.	0.9	0
103	SAT0473â€Predictive Factors of Longitudinal Bone Loss in Patients Treated with Aromatase Inhibitors for Breast Cancer. Annals of the Rheumatic Diseases, 2014, 73, 764.3-765.	0.9	0
104	SAT0472â€The Effect of Aromatase Inhibitors on Different Sites of the Human Skeleton – an Observational Case-Control Study. Annals of the Rheumatic Diseases, 2014, 73, 764.2-764.	0.9	0
105	FRI0285â€The Effect of Steroids on Fracture, Adjusting for Bone Mineral Density. Annals of the Rheumatic Diseases, 2015, 74, 527.4-528.	0.9	0
106	FRI0303â€The Effect of Secondary Amenorrhoea on Bone Mineral Density. Annals of the Rheumatic Diseases, 2015, 74, 534.1-534.	0.9	0
107	SAT0289â€Predictors of Fragility Humeral Fractures: An Observational Study. Annals of the Rheumatic Diseases, 2015, 74, 763.1-763.	0.9	0
108	AB0788â€Predictors of Fractures in Excessive Consumption of Alcohol: An Observational Study:. Annals of the Rheumatic Diseases, 2016, 75, 1173.3-1173.	0.9	0

#	Article	IF	CITATIONS
109	THU0068â€Absolute Monocyte Counts Are Associated with Adverse EULAR Response after 6 Months of Treatment with A Biologic Agent for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 203.1-203.	0.9	0
110	THU0462â€The Predictors of Fracture in Patients with Coeliac Disease: An Observational Study: Table 1. Annals of the Rheumatic Diseases, 2016, 75, 359.3-359.	0.9	0
111	FRI0383â€Predictors of Fragility Fractures in Patients with Polymyalgia Rheumatica on Steroids: An Observational Study: Table 1. Annals of the Rheumatic Diseases, 2016, 75, 573.1-573.	0.9	0
112	THU0482â€Predictors of Fractures in Patients with Untreated Early Menopause: An Observational Study. Annals of the Rheumatic Diseases, 2016, 75, 366.1-366.	0.9	0
113	THU0101â€The Predictors of Fragility Fracture in Patients with Rheumatoid Arthritis: An Observational Study:. Annals of the Rheumatic Diseases, 2016, 75, 215.3-216.	0.9	0
114	AB0796â€The Predictors of Fracture in Patients with Hyperparathyroidism: An Observational Study: Table 1. Annals of the Rheumatic Diseases, 2016, 75, 1176.1-1176.	0.9	0
115	New use for tociluzimab in giant cell arteritis. Rheumatology, 2017, 56, kew489.	1.9	0
116	Effects of superoxide dismutase on chondrocytes in osteoarthropathy of alkaptonuria. Osteoarthritis and Cartilage, 2017, 25, S148-S149.	1.3	0
117	FRI0543â€Which factors can help predict fragility fractures in patients diagnosed with inflammatory bowel disease? a case-control study. , 2017, , .		0
118	FRI0560â€Predictors of fractures in female patients with anorexia. , 2017, , .		0
119	FRI0565â€Fragility fractures in patients on depo-provera are not associated with usual risk factors for fracture. , 2017, , .		0
120	FRI0538â€Evaluation of factors that increase fracture risk in breast cancer. , 2017, , .		0
121	AB0260â€The predictors of fragility fractures in patients on aromatase inhibitors: an observational study. , 2017, , .		0
122	THU0699â€Predictors of fracture and low bone mineral density in patients with history of parental fracture. , 2018, , .		0
123	AB0375â€A systematic literature review of omega 3 in the treatment of rheumatoid arthritis. , 2018, , .		0
124	Better is possible. Rheumatology, 2019, 58, 741-742.	1.9	0
125	An atypical presentation of subacute cutaneous lupus erythematous. Rheumatology, 2019, 58, 2142-2142.	1.9	0
126	FRI0503â€USING BONE MINERAL DENSITY VERSUS THE RATIO OF BODY MASS INDEX TO BONE MINERAL DEN TO PREDICT FRACTURE RISK IN HYPERTHYROIDISM. , 2019, , .	ISITY	0

#	Article	IF	CITATIONS
127	FRIO482â€RISK FACTORS FOR FRAGILITY FRACTURE IN PATIENTS WHO SMOKE: AN OBSERVATIONAL STUDY. , 2019, , .		0
128	FRI0638â€LUMBAR SPINE BONE MASS DENSITY AS A PREDICTOR OF FRACTURES IN PATIENTS WITH COELIAC DISEASE: AN OBSERVATIONAL STUDY. , 2019, , .		0
129	AB0483â€A SYSTEMATIC LITERATURE REVIEW ON THE USE OF BIOLOGICS IN SJÖGREN'S SYNDROME. , 2	019,,.	0
130	SAT0246â€USING BONE MINERAL DENSITY VERSUS THE RATIO OF BODY MASS INDEX TO BONE MINERAL DENSITY TO PREDICT FRACTURE RISK IN POLYMYALGIA RHEUMATICA. , 2019, , .		0
131	Comment on: Should Rheumatology be a core discipline of a chronic pain multi-disciplinary team?: reply. Rheumatology, 2019, 58, 185-186.	1.9	0
132	P101â $\in$ fIdentifying factors that predict fracture risk in polymyalgia rheumatica. Rheumatology, 2021, 60, .	1.9	0
133	Empathic communication during a pandemic: How can we minimize the deficit?. Rheumatology, 2021, 60, SI1-SI2.	1.9	0
134	The role of 14-3-3 η as a biomarker in rheumatoid arthritis. Rheumatology and Immunology Research, 2021, 2, 87-90.	0.8	0
135	AB0213â€Correlation between components of the das28 score and health assessment questionnaire in early rheumatoid arthritis. , 2018, , .		0
136	AB0996â€Bone mineral density at different sites as a predictor of rib fractures: a case-control study. , 2018, , .		0
137	SAT0705â€Association between fracture sites in patients with a history of parental fracture. , 2018, , .		0
138	A deeper dive into rare autoimmune diseases, death and COVID-19 in the first wave of the pandemic. Rheumatology, 2021, , .	1.9	0
139	Comment on: Paradoxically protective effect of glucocorticoids on bone mass and fragility fracture in a large cohort: a cross sectional study. Reply. Rheumatology Advances in Practice, 2022, 6, rkac011.	0.7	0
140	Cluster analysis demonstrates co-existing sites of fragility fracture and associated comorbidities. Osteoporosis International, 2022, , 1.	3.1	0